Cover Image
市場調查報告書

念珠菌感染:開發平台分析

Candidiasis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192515
出版日期 內容資訊 英文 147 Pages
訂單完成後即時交付
價格
Back to Top
念珠菌感染:開發平台分析 Candidiasis - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 147 Pages
簡介

念珠菌感染主要是感染白色念珠球菌這種念珠菌而引起。皮膚的念珠球菌感染症特徵為清楚的出現紅斑、皮膚癢、許多情況下還會有體液滲出。也常見有瘡痂、膿皰。常見於鼠蹊部·臀部內側等、胸部中間、腳趾間、手指間、臍帶等也很常見。治療方法包含抗真菌藥物等。

本報告提供念珠菌感染的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

念珠菌感染概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Amplyx Pharmaceuticals, Inc.
  • Bakker Medical Srl
  • Biomar Microbial Technologies
  • Cellceutix Corporation
  • Cidara Therapeutics, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • General Biologicals Corporation
  • Grupo Ferrer Internacional, S.A.
  • Hsiri Therapeutics, LLC
  • Nanomerics Ltd
  • Novabiotics Limited
  • NovaDigm Therapeutics, Inc.
  • Onxeo SA
  • Panacela Labs, Inc.
  • Scynexis, Inc.
  • Sealife PHARMA GMBH
  • TGV-Laboratories
  • Viamet Pharmaceuticals, Inc.
  • Wellstat Vaccines, LLC

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 61894700
  • AC-17
  • amphotericin b
  • amphotericin B
  • amphotericin B
  • APX-001
  • arasertaconazole
  • Candida vaccine
  • candidiasis vaccine
  • CD-101
  • CTIX-1502
  • DWP-06081
  • Forazoline A
  • KSL-W
  • MH-010
  • miconazole nitrate
  • Monoclonal Antibodies to Target Fba for Candidiasis
  • mutanobactins
  • Myc-102
  • NDV-3
  • NDV-3A
  • NP-339
  • obliquumol
  • PAC-113
  • pegylated amphotericin B
  • PMX-1408
  • PMX-1570
  • PMX-1576
  • PMX-1591
  • PMX-1625
  • PMX-519
  • PMX-70004
  • Prof-002
  • Recombinant Peptides for Oropharyngeal Candidiasis
  • SCY-078
  • SLP-0901
  • SLP-0904
  • Small Molecule for Bacterial Vaginosis and Candidiasis
  • Small Molecule for Fungal Infections
  • Small Molecule for Systemic Candidiasis
  • Small Molecules for Aspergillosis and Candidiasis
  • Small Molecules for Candidiasis
  • Small Molecules for Candidiasis
  • Small Molecules for Candidiasis
  • Small Molecules for Fungal Infections
  • Small Molecules for Fungal Infections
  • Synthetic Peptide for Multi-Drug Resistant Microbial Infections
  • VT-1161
  • XELRYX-3

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9085IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 4, 20 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Candidiasis - Overview 8
  • Candidiasis - Therapeutics Development 9
  • Pipeline Overview 9
  • Pipeline by Companies 10
  • Pipeline by Universities/Institutes 13
  • Products under Development by Companies 15
  • Products under Development by Universities/Institutes 18
  • Candidiasis - Therapeutics Assessment 19
  • Assessment by Target 19
  • Assessment by Mechanism of Action 21
  • Assessment by Route of Administration 23
  • Assessment by Molecule Type 25
  • Candidiasis - Companies Involved in Therapeutics Development 27
  • Amplyx Pharmaceuticals Inc 27
  • Bakker Medical Srl 27
  • Biomar Microbial Technologies 28
  • Biosergen AS 28
  • Cidara Therapeutics Inc 29
  • CSA Biotechnologies LLC 29
  • Daewoong Pharmaceutical Co Ltd 30
  • Dermala Inc 30
  • General Biologicals Corp 31
  • Grupo Ferrer Internacional SA 31
  • Hsiri Therapeutics LLC 32
  • iCo Therapeutics Inc. 32
  • ImmunoClin Corp 33
  • Matinas BioPharma Holdings Inc 33
  • Nanomerics Ltd 34
  • NovaDigm Therapeutics Inc 34
  • Novartis AG 35
  • Onxeo SA 35
  • Scynexis Inc 36
  • Sealife PHARMA GMBH 36
  • Viamet Pharmaceuticals Inc 37
  • Visterra Inc 37
  • Wellstat Vaccines LLC 38
  • Candidiasis - Drug Profiles 39
  • (clotrimazole + diclofenac sodium) - Drug Profile 39
  • 61894700 - Drug Profile 40
  • AC-17 - Drug Profile 41
  • amphotericin B - Drug Profile 42
  • amphotericin B - Drug Profile 44
  • amphotericin B - Drug Profile 48
  • Amphotericin B sodium - Drug Profile 49
  • Antibody to Target Ece1 for Candidiasis - Drug Profile 51
  • APX-001 - Drug Profile 52
  • APX-001A - Drug Profile 54
  • arasertaconazole - Drug Profile 55
  • B-4010 - Drug Profile 56
  • BL-5923 - Drug Profile 57
  • BSG-005 - Drug Profile 58
  • candidiasis vaccine - Drug Profile 59
  • CD-101 - Drug Profile 60
  • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 64
  • CSA-13 - Drug Profile 65
  • Drug for Candidiasis - Drug Profile 67
  • DWP-06081 - Drug Profile 68
  • Forazoline A - Drug Profile 69
  • iCo-010 - Drug Profile 70
  • interleukin-22 - Drug Profile 71
  • JSM-11 - Drug Profile 72
  • KSL-W - Drug Profile 73
  • miconazole nitrate - Drug Profile 74
  • Monoclonal Antibodies for Candidiasis - Drug Profile 76
  • Monoclonal Antibody for Candidiasis - Drug Profile 77
  • Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile 78
  • mutanobactin A - Drug Profile 79
  • NDV-3 - Drug Profile 80
  • NDV-3A - Drug Profile 82
  • NP-339 - Drug Profile 84
  • obliquumol - Drug Profile 85
  • Occidiofungin - Drug Profile 86
  • P-113Du - Drug Profile 87
  • P-113Tri - Drug Profile 88
  • PAC-113 - Drug Profile 89
  • Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile 91
  • Prof-002 - Drug Profile 92
  • Recombinant Enzyme for Candidiasis - Drug Profile 93
  • Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 94
  • SCY-078 - Drug Profile 95
  • SLP-0901 - Drug Profile 100
  • SLP-0904 - Drug Profile 101
  • Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 102
  • Small Molecule for Fungal Infections - Drug Profile 103
  • Small Molecules for Aspergillosis and Candidiasis - Drug Profile 104
  • Small Molecules for Candidiasis - Drug Profile 105
  • Small Molecules for Candidiasis - Drug Profile 106
  • Small Molecules for Candidiasis - Drug Profile 107
  • Small Molecules for Fungal Infections - Drug Profile 108
  • Small Molecules for Fungal Infections - Drug Profile 109
  • Small Molecules for Systemic Candidiasis - Drug Profile 110
  • Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile 111
  • Synthetic Peptides for Candidiasis - Drug Profile 112
  • Synthetic Peptides for Infections Diseases and Oncology - Drug Profile 113
  • TOL-463 - Drug Profile 114
  • Vaccine to Target Ece1 for Candidiasis - Drug Profile 115
  • Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile 116
  • VIS-FNG - Drug Profile 117
  • VT-1129 - Drug Profile 118
  • VT-1161 - Drug Profile 120
  • Candidiasis - Dormant Projects 126
  • Candidiasis - Discontinued Products 129
  • Candidiasis - Product Development Milestones 130
  • Featured News & Press Releases 130
  • Appendix 141
  • Methodology 141
  • Coverage 141
  • Secondary Research 141
  • Primary Research 141
  • Expert Panel Validation 141
  • Contact Us 141
  • Disclaimer 142

List of Tables

  • Number of Products under Development for Candidiasis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2017
  • Candidiasis - Pipeline by Bakker Medical Srl, H1 2017
  • Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2017
  • Candidiasis - Pipeline by Biosergen AS, H1 2017
  • Candidiasis - Pipeline by Cidara Therapeutics Inc, H1 2017
  • Candidiasis - Pipeline by CSA Biotechnologies LLC, H1 2017
  • Candidiasis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Candidiasis - Pipeline by Dermala Inc, H1 2017
  • Candidiasis - Pipeline by General Biologicals Corp, H1 2017
  • Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H1 2017
  • Candidiasis - Pipeline by Hsiri Therapeutics LLC, H1 2017
  • Candidiasis - Pipeline by iCo Therapeutics Inc., H1 2017
  • Candidiasis - Pipeline by ImmunoClin Corp, H1 2017
  • Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
  • Candidiasis - Pipeline by Nanomerics Ltd, H1 2017
  • Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H1 2017
  • Candidiasis - Pipeline by Novartis AG, H1 2017
  • Candidiasis - Pipeline by Onxeo SA, H1 2017
  • Candidiasis - Pipeline by Scynexis Inc, H1 2017
  • Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2017
  • Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
  • Candidiasis - Pipeline by Visterra Inc, H1 2017
  • Candidiasis - Pipeline by Wellstat Vaccines LLC, H1 2017
  • Candidiasis - Dormant Projects, H1 2017
  • Candidiasis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Candidiasis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Candidiasis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Candidiasis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top